DK0626853T3 - Anvendelse af substituerede adeninderivater til behandling af multipel sclerose - Google Patents

Anvendelse af substituerede adeninderivater til behandling af multipel sclerose

Info

Publication number
DK0626853T3
DK0626853T3 DK93906071T DK93906071T DK0626853T3 DK 0626853 T3 DK0626853 T3 DK 0626853T3 DK 93906071 T DK93906071 T DK 93906071T DK 93906071 T DK93906071 T DK 93906071T DK 0626853 T3 DK0626853 T3 DK 0626853T3
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
treatment
adenine derivatives
substituted adenine
formula
Prior art date
Application number
DK93906071T
Other languages
Danish (da)
English (en)
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0626853T3 publication Critical patent/DK0626853T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK93906071T 1992-02-19 1993-02-18 Anvendelse af substituerede adeninderivater til behandling af multipel sclerose DK0626853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK0626853T3 true DK0626853T3 (da) 2000-08-07

Family

ID=25277387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93906071T DK0626853T3 (da) 1992-02-19 1993-02-18 Anvendelse af substituerede adeninderivater til behandling af multipel sclerose

Country Status (15)

Country Link
US (4) US5310732A (no)
EP (1) EP0626853B1 (no)
JP (1) JP2688113B2 (no)
AT (1) ATE192045T1 (no)
AU (1) AU682818B2 (no)
BR (1) BR9305907A (no)
CA (1) CA2130275C (no)
CH (1) CH684310A5 (no)
DE (1) DE69328474T2 (no)
DK (1) DK0626853T3 (no)
FI (1) FI943805A7 (no)
HU (1) HU218656B (no)
NO (2) NO309025B1 (no)
RU (1) RU2130308C1 (no)
WO (1) WO1993016706A1 (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
EP0642347A4 (en) * 1992-05-19 1997-06-18 Scripps Research Inst USE OF 2-HALO-ADENINE DERIVATIVES AS THERAPEUTIC ACTIVE AGENTS AGAINST CHRONIC-MYELOIC LEUKEMIA.
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US7094597B1 (en) 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
AU7470794A (en) * 1994-05-26 1995-12-21 Scripps Research Institute, The 2-halo-2'-deoxyadenosine treatement for inflammatory bowel disease
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5817641A (en) * 1994-07-21 1998-10-06 Thomas Jefferson University Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
EP0801571B1 (en) * 1994-12-22 2002-09-04 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
IL117090A (en) * 1995-02-10 2000-07-26 Schering Ag Pharmaceutical compositions containing oxazolidinone derivatives
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
AU3851601A (en) * 2000-02-18 2001-08-27 Southern Res Inst Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-9h- purin-6-amine
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
AU2002220038A1 (en) 2000-11-01 2002-05-15 Alberto Martini Immunomodulatory peptides derived from heat shock proteins and uses thereof
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
EP1551386A4 (en) * 2002-09-27 2009-03-25 Bioenvision Inc METHOD AND COMPOSITIONS FOR TREATING LUPUS WITH CLOFARABIN
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
DK2272503T3 (da) * 2003-03-28 2013-05-21 Ares Trading Sa Orale formuleringer af cladribin
WO2004087100A2 (en) * 2003-03-28 2004-10-14 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
JP2007517019A (ja) * 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
ATE431740T1 (de) * 2004-12-22 2009-06-15 Merck Serono Sa Kombinationstherapie gegen multiple sklerose
EP2275110B1 (en) 2004-12-22 2013-07-10 Merck Serono SA Cladribine regimen for treating Multiple Sclerosis
CA2595126A1 (en) 2005-01-14 2006-07-20 The Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
RU2393866C2 (ru) * 2005-03-17 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Применение 5'-метилтиоаденозина (мта) для предотвращения и/или лечения аутоиммунных заболеваний и/или отторжения трансплантата
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
US11493428B2 (en) 2013-03-15 2022-11-08 Gpb Scientific, Inc. On-chip microfluidic processing of particles
US12590955B2 (en) 2013-03-15 2026-03-31 Zeon Corporation Methods and systems for processing particles
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP3608022A1 (en) 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
US9839625B2 (en) 2014-11-06 2017-12-12 Northwestern University Inhibition of cancer cell motility
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
CA2996529A1 (en) * 2015-08-24 2017-03-02 Gpb Scientific, Llc Methods and devices for multi-step cell purification and concentration
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
IL305567A (en) 2021-03-03 2023-10-01 Ares Trading Sa Method for predicting the response of a patient treated with cladribine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572070C3 (de) * 1966-03-12 1979-03-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Kopiermaterial
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
EP0314011A3 (de) * 1987-10-30 1990-04-11 F. Hoffmann-La Roche Ag Purinderivate
WO1989008658A1 (en) * 1988-03-16 1989-09-21 Scripps Clinic And Research Foundation Substituted adenine derivatives useful as therapeutic agents
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
ATE192045T1 (de) 2000-05-15
CA2130275A1 (en) 1993-09-02
AU682818B2 (en) 1997-10-23
EP0626853B1 (en) 2000-04-26
EP0626853A1 (en) 1994-12-07
FI943805L (fi) 1994-10-19
FI943805A7 (fi) 1994-10-19
FI943805A0 (fi) 1994-08-18
NO942765D0 (no) 1994-07-25
CA2130275C (en) 1999-06-29
BR9305907A (pt) 1997-10-21
RU94038043A (ru) 1996-11-20
US5310732A (en) 1994-05-10
NO309025B1 (no) 2000-12-04
HUT68030A (en) 1995-05-29
DE69328474D1 (de) 2000-05-31
US5506213A (en) 1996-04-09
RU2130308C1 (ru) 1999-05-20
AU3724993A (en) 1993-09-13
CH684310A5 (de) 1994-08-31
JP2688113B2 (ja) 1997-12-08
JPH07507540A (ja) 1995-08-24
WO1993016706A1 (en) 1993-09-02
HU9402392D0 (en) 1994-10-28
NO20000762D0 (no) 2000-02-16
HU218656B (hu) 2000-10-28
NO942765L (no) 1994-09-13
US5506214A (en) 1996-04-09
DE69328474T2 (de) 2000-09-28
NO20000762L (no) 1994-09-13
NO322328B1 (no) 2006-09-18
US5541164A (en) 1996-07-30

Similar Documents

Publication Publication Date Title
DK0626853T3 (da) Anvendelse af substituerede adeninderivater til behandling af multipel sclerose
ATE245646T1 (de) Therapeutische nukleoside
RU95113454A (ru) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
NO990708D0 (no) Bisykliske pyrimidinderivater og deres anvendelse som antikoagulanter
DE69109125D1 (de) Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
ES2067314T3 (es) 3-benzacepin-zonas sustituidas por un grupo benzociclobutilo o indanil-alquil-amino-alquilo, utiles en el tratamiento de las afecciones cardiovasculares.
ATE251141T1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
IN172468B (no)
FI895447A0 (fi) Substituerade adeninderivat anvaendbara som terapeutiska substanser.
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
NO932377D0 (no) Antivirale forbindelser
DE69416518D1 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
DK190983A (da) 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
YU4393A (sr) Supstituisani heksahidroazepinoni i tetrahidrobenzazepinoni
SE8107468L (sv) Komposition for behandling av psoriasis pa basis av en 1,8-dihydroxi-9-antron substituerad i 10-stellningen
DE69418050D1 (de) Antivirale analoge von difluorostaton
NO305556B1 (no) Tiokarbamoylforbindelser og anvendelse derav samt middel for beskyttelse av tekniske materialer
DK0512953T3 (da) Fremgangsmåde til fremstilling af benzensulfonamider